Company / Cost of Revenue
Orchestra BioMed Holdings, Inc. Cost of Revenue History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$204.0K
FY2025
5-year range
$186.0K / $211.0K
FY2023-FY2025
Trend
+9.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $211,000 to $204,000 over the past 2 years.
Based on SEC 10-K filings.
$204,000 in FY2025.
Improved from $211,000 to $204,000 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cost of revenue increased 9.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $204.0K | +9.7% |
| FY2024 | $186.0K | -11.8% |
| FY2023 | $211.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026